# A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene

> **NCT05469178** · PHASE1,PHASE2 · TERMINATED · sponsor: **BerGenBio ASA** · enrollment: 26 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Bemcentinib
- **DRUG:** Pembrolizumab
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT05469178
- **Lead sponsor:** BerGenBio ASA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-03
- **Primary completion:** 2025-04-03
- **Final completion:** 2025-04-03
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2025-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05469178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05469178, "A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05469178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*